Published in Ann Surg Oncol on December 20, 2008
Retroperitoneal tumours: review of management. Ann R Coll Surg Engl (2011) 1.42
Retroperitoneal liposarcoma: current insights in diagnosis and treatment. Front Surg (2015) 0.95
Abdominal soft tissue sarcoma: a multicenter retrospective study. Int J Clin Oncol (2010) 0.82
Surgical management of retroperitoneal and pelvic sarcomas. J Surg Oncol (2014) 0.82
Heterogeneity and immunophenotypic plasticity of malignant cells in human liposarcomas. Stem Cell Res (2013) 0.81
Can Abdominal Computed Tomography Imaging Help Accurately Identify a Dedifferentiated Component in a Well-Differentiated Liposarcoma? J Comput Assist Tomogr (2016) 0.78
The modified frailty index to predict morbidity and mortality for retroperitoneal sarcoma resections. J Surg Res (2017) 0.75
Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. Ther Adv Med Oncol (2017) 0.75
MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst (2005) 5.22
Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol (2012) 4.44
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
Steps toward mapping the human vasculature by phage display. Nat Med (2002) 3.82
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood (2006) 3.48
Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol (2004) 3.02
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood (2007) 2.91
Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res (2010) 2.82
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol (2012) 2.77
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol (2007) 2.72
Soft tissue sarcomas. CA Cancer J Clin (2004) 2.65
Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer (2003) 2.64
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant (2011) 2.63
Breast cancer on the world wide web: cross sectional survey of quality of information and popularity of websites. BMJ (2002) 2.53
Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol (2002) 2.51
Career satisfaction, practice patterns and burnout among surgical oncologists: report on the quality of life of members of the Society of Surgical Oncology. Ann Surg Oncol (2007) 2.50
Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol (2008) 2.48
Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol (2006) 2.43
Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol (2007) 2.40
A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol (2008) 2.39
Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A (2007) 2.38
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene (2005) 2.34
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34
Optimizing treatment of desmoid tumors. J Clin Oncol (2007) 2.27
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood (2010) 2.25
Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol (2011) 2.23
Body surface area and body weight predict total liver volume in Western adults. Liver Transpl (2002) 2.21
Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res (2005) 2.14
Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol (2002) 2.13
Intraductal papillary mucinous neoplasm of the pancreas: associated cancers, family history, genetic predisposition? Surgery (2011) 2.11
Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg (2009) 2.04
The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell (2012) 2.02
Angiosarcoma of the breast. Cancer (2005) 1.98
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant (2008) 1.96
A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res (2005) 1.95
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood (2014) 1.95
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood (2013) 1.87
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer (2007) 1.83
Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood (2010) 1.82
Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.82
Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol (2012) 1.80
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
Increasing the pool of academically oriented African-American medical and surgical oncologists. Cancer (2003) 1.77
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma (2014) 1.77
High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation (2009) 1.76
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood (2011) 1.75
Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol (2006) 1.72
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant (2002) 1.71
Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg (2002) 1.70
ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol (2009) 1.70
Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study. Cancer (2007) 1.70
A strategy for ZnO nanorod mediated multi-mode cancer treatment. Biomaterials (2010) 1.70
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 1.67
Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann Surg Oncol (2014) 1.67
Protective importance of the myogenic response in the renal circulation. Hypertension (2009) 1.67
Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer (2011) 1.66
MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas. Surgery (2013) 1.64
Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res (2008) 1.64
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int (2013) 1.63
Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood (2011) 1.61
Modeling study of air pollution due to the manufacture of export goods in China's Pearl River Delta. Environ Sci Technol (2006) 1.57
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant (2005) 1.55
Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A (2008) 1.54
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer (2011) 1.50
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer (2007) 1.46
Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg (2003) 1.45
Neurocognitive function before and after surgery for insular gliomas. J Neurosurg (2011) 1.44
Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol (2011) 1.43
Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol (2004) 1.41
Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One (2009) 1.40
A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J (2014) 1.40
Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res (2009) 1.40
Novel treatment for desmoplastic small round cell tumor: hyperthermic intraperitoneal perfusion. J Pediatr Surg (2010) 1.40
Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer (2007) 1.39
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst (2006) 1.39
Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. Gastroenterology (2012) 1.38
Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer (2010) 1.37
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer (2010) 1.37
Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther (2007) 1.36
Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol (2013) 1.35
Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg (2002) 1.35
Soft tissue sarcoma. J Natl Compr Canc Netw (2010) 1.34
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant (2010) 1.34
Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther (2009) 1.33